We have generated recombinant adenoviruses encoding three genetically modified surface antigens (SAGs) of the parasite Toxoplasma gondii, that is, AdSAG1, AdSAG2, and AdSAG3. Modifications included the removal of their glycosylphosphatidylinositol (GPI) anchoring motifs and, in some cases, the exchange of the native signal peptide for influenza virus hemagglutinin signal sequence. Adenovirus immunization of BALB/c mice elicited potent antibody responses against each protein, displaying a significant bias toward a helper T cell type 1 (Th1) profile in animals vaccinated with AdSAG1. Furthermore, the presence of parasite-specific IFN-␥-producing T cells was analyzed by proliferation assays and enzyme-linked immunospot assays in the same animals. Splenocytes from immunized mice secreted IFN-␥ after in vitro stimulation with tachyzoite lysate antigen or with a fraction enriched for membrane-purified GPI-anchored proteins (F3) from the T. gondii tachyzoite surface. Epitopes recognized by CD8 ؉ T cells were identified in SAG1 and SAG3, but not SAG2, sequences, although this protein also induced a specific response. We also tested the capacity of the immune responses detected to protect mice against a challenge with live T. gondii parasites. Although no protection was observed against tachyzoites of the highly virulent RH strain, a significant reduction in cyst loads in the brain was observed in animals challenged with the P-Br strain. Thus, up to 80% of the cysts were eliminated from animals vaccinated with a mixture of the three recombinant viruses. Because adenoviruses seemed capable of inducing Th1-biased protective immune responses against T. gondii antigens, other parasite antigens should be tested alone or in combination with those described here to further develop a protective vaccine against toxoplasmosis.
INTRODUCTION T
HE COCCIDIAN PROTOZOAN Toxoplasma gondii is an obligate intracellular parasite that can be found in most regions of the world. Toxoplasma gondii has a wide host range and is transmitted from animals to humans, mainly by ingestion of cysts in raw or undercooked meat or by sporulated oocysts found in feces of domestic cats (Dubey et al., 1998) . Toxoplasmosis has major importance as a prenatal disease, being responsible for abortions or congenital defects, and as an opportunistic infection in immunocompromised individuals, with high mortality rates due to encephalitis during reactivation of chronic infections (Luft and Remington, 1992) . Thus, vaccines against T. gondii may help to control disease development and prevent transmission of the parasite within risk groups.
Vaccine development is based on the observation that exposure to T. gondii can elicit a life-long immune response, capable of protecting the host against a secondary challenge with the parasite (Denkers and Gazzinelli, 1998) . In early stages of infection, this response is characterized by activation of innate mechanisms mediated by macrophages and dendritic cells (Reis e Sousa et al., 1997) , which internalize tachyzoites or tachyzoite products and produce interleukin (IL)-12, and by natural killer (NK) cells, which secrete interferon-␥ (IFN-␥) (Gazzinelli et al., , 1994 Sher et al., 1993) . This last cytokine controls the replication of the parasite and, in conjunction with IL-12, drives the differentiation of CD4 ϩ T lymphocytes specific for parasite antigens to a helper T cell type 1 (Th1) cytokine profile. In addition, CD8 ϩ T cells are crucial to control parasite replication in the chronic phase of the disease, preventing reactivation of infection. Both CD4 ϩ and CD8 ϩ T cells secrete IFN-␥, and CD8 ϩ T lymphocytes develop cytotoxic activity against infected cells (Suzuki and Remington, 1988; Brown and McLeod, 1990; Subauste et al., 1991) .
Initial attempts to induce protection against toxoplasmosis involved the use of live attenuated tachyzoites from mutant strains of T. gondii, such as the temperature-sensitive ts-4 strain (Gazzinelli et al., 1991; Hiramoto et al., 2002) . Despite the high efficiency in terms of activation of CD4 ϩ and CD8 ϩ T cells and the efficacy of protection, vaccines based on live tachyzoites are not applicable to humans, because of the risk of pathogenic side effects. Therefore, most of the more recent protocols have focused on development of recombinant vaccines. As target antigens, there is great interest in tachyzoite surface proteins, particularly surface antigen-1 (SAG1) (Letscher-Bru et al., 1998; Petersen et al., 1998; Nielsen et al., 1999; Angus et al., 2000; Haumont et al., 2000; Bonenfant et al., 2001; Couper et al., 2003) . In addition, a few studies have also been performed with SAG2 and SAG3 (Mishima et al., 2001) . The SAG proteins, the most abundant on the tachyzoite surface, are anchored to the parasite membrane by glycosylphosphatidylinositol (GPI) structures and are believed to be involved in the process of host cell invasion. Furthermore, their sequences are highly conserved among different strains of T. gondii, sharing a high degree of homology between type I (pathogenic and lethal to mice) and type II/III (cystogenic) strains (Lekutis et al., 2001) .
Genes encoding T. gondii surface antigens SAG1 and SAG2 have been cloned and expressed in recombinant prokaryotic and eukaryotic systems, and both recombinant proteins and DNA plasmid molecules have been used to immunize mice and other species. It was observed that recombinant proteins generally induce high titers of IgG1 antibodies, which respond weakly to challenge with pathogenic strains of T. gondii (Petersen et al., 1998) , and that improvement of the response depends on combination with proper adjuvants (Letscher-Bru et al., 1998; Haumont et al., 2000) . On the other hand, vaccines based on plasmids encoding SAG1 and SAG2 were able in many cases, depending on administration route and formulation, to induce a cellular immune response with a Th1 profile, inducing better protection (Nielsen et al., 1999; Angus et al., 2000) . In this context, viral vectors such as adenoviruses can improve the immune responses in comparison with naked plasmid vaccines, because they are more efficient in transferring the genetic sequences and inducing protein expression. Adenoviruses infect a great variety of cells, including key immune cells, such as dendritic cells, which may be the reason for their high immunogenicity when compared with other viruses (Mercier et al., 2002; Worgall et al., 2004) . Because of these characteristics, adenoviruses are efficient activators of CD4 ϩ and CD8 ϩ T cells and are capable of driving the immune response toward the desired Th1 profile. We constructed replication-deficient recombinant adenoviruses to express SAG1, SAG2, or SAG3 of T. gondii, and vaccinated mice in order to induce a protective immune response against challenge with the live parasite. Our results show that all the recombinant adenoviruses expressing the various tachyzoite surface antigens were immunogenic, inducing high levels of antigen-specific IgG2a as well as IFN-␥ that led to reduction of brain cyst formation in mice challenged with the P-Br strain.
MATERIALS AND METHODS

Mice
Female BALB/c mice, 6 to 8 weeks old, were obtained from the animal facilities of the Federal University of Minas Gerais (Centro de Bioterismo [CEBIO] , Belo Horizonte, Brazil) and housed according to institutional standard guidelines.
Parasites and antigens
Strains RH (Sabin, 1941) and P-Br (Fux et al., 2003) were used for challenge of vaccinated mice. The RH strain was maintained by successive inoculation of free tachyzoites in Swiss Webster mice, and is obtained by peritoneal washing of infected animals with phosphate-buffered saline (PBS). The P-Br strain is maintained by successive inoculation of cysts by oral gavage in Swiss mice, and is obtained from brains of infected animals 45 days after inoculation. RH strain tachyzoites were also employed in preparation of total tachyzoite lysate antigen (TLA) and to obtain the F3 antigenic fraction, which consists of an extract of GPI-anchored proteins purified from tachyzoite membrane, as previously described (Giraldo et al., 2000) .
Synthetic peptides
We used SYFPEITHI software (http://www.syfpeithi.de/ Scripts/MHCServer.dll/EpitopePrediction.htm) to predict BALB/ c class I MHC-binding peptides from SAG1, SAG2, and SAG3 proteins. For each protein, a panel of H2-K d -and H2-L d -binding nonamers was obtained. The H2-L d -specific peptides TPTENHFTL and DSTLGPVKL (SAG1), GPSSGSVVF (SAG2), and YPESGPVNL and HPQPSTYTL (SAG3), which presented the maximal score (Ն21), were selected to be used in enzyme-linked immunospot (ELISPOT) and cytokine production assays. The peptides were prepared according to a standard N ␣ -9-fluorenylmethyloxycarbonyl (Fmoc) strategy on a PSSM8 multispecific peptide synthesizer (Shimadzu, Kyoto, Japan) by solid-phase synthesis and were purified by high-performance liquid chromatography in a Shimadzu system. Peptide identities were confirmed with a Micromass Q-Tof Micro equipped with an electrospray ionization source (Micromass MS Technologies, Division of Waters, Milford, MA).
Cell lines
HEK 293 cells (CRL-1573; American Type Culture Collection [ATCC], Manassas, VA) were used for recombinant adenovirus construction and amplification. This lineage is transformed with adenovirus type 5 sequences corresponding to viral genomic region E1, and is permissive to replication of ⌬E1 adenovirus (Shaw et al., 2002) . NIH/3T3 fibroblasts (CRL-1658; ATCC) were used as antigen-presenting cells (APCs) in ELISPOT assays. Cells were grown at 37°C and 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM; Sigma, St. Louis, MO) supplemented with 5% fetal bovine serum (FBS; GIBCO/Invitrogen, Grand Island, NY), 5 mM sodium bicarbonate, 25 mM HEPES, and gentamicin at 40 g/ml (complete DMEM).
Recombinant adenoviruses
Genes encoding the SAG antigens were amplified from the tachyzoite genome (strain RH) by polymerase chain reaction (PCR). For amplification of SAG1 and SAG2, primers were designed to exclude the 3Ј segment encoding GPI motifs. The two PCR products were cloned into BglII and HindIII sites of the eukaryotic expression cassette of an adenovirus shuttle vector. For SAG3, primers were designed to exclude the 3Ј GPI motif and the 5Ј signal sequence. The PCR product was cloned into EcoRI and BamHI sites of pcDNA3.1 (Invitrogen, Carlsbad, CA), in frame with the hemagglutinin signal sequence (HASS) of influenza virus. The chimeric HASS-SAG3 sequence was cut from pcDNA3.1 and subcloned into the expression cassette of an adenovirus shuttle vector. All constructs were tested for protein expression by transfection into HEK 293 cells and Western blot analysis of transfected cell extracts. The recombinant adenoviruses were generated by intracellular homologous recombination between the shuttle vectors carrying SAG sequences and plasmid pJM17, which carries a nonreplicative ⌬E1 adenovirus type 5 genome (McGrory et al., 1988) . To obtain recombination, both shuttle vector and pJM17 were transfected into permissive (E1-transgenic) HEK 293 cells, using calcium chloride as previously described (Chen and Okayama, 1988) . Adenoviruses were purified from HEK 293 cell extracts by cesium chloride isopycnic banding, and were frozen at Ϫ70°C in 10% glycerol after extensive dialysis against 100 mM Tris, pH 8.0.
ELISA and Western blot
The enzyme-linked immunosorbent assay (ELISA) was performed as previously described (Giraldo et al., 2000) . Briefly, plates were coated overnight at 4°C with membrane F3 antigenic fraction (1 g/ml) and blocked with PBS-2% casein for 2 hr at 37°C. Serum was diluted 1:100 in PBS-0.01% Tween 20 and incubated for 2 hr. Secondary antibodies consisted of peroxidase-conjugated goat anti-mouse IgG, IgG1, and IgG2a (diluted 1:1000; Sigma) and were incubated for 45 min. Reactions were detected with 3,3Ј,5,5Ј-tetramethylbenzidine (TMB) reagent (Sigma) and read at 450 nm. For Western blot analysis, antigen samples (5-10 g of protein per sample) were run in 12% polyacrylamide gels under denaturing conditions and transferred onto nitrocellulose membranes. Membranes were blocked overnight at 4°C with 5% skimmed milk and 0.1% Tween 20 in PBS. Sera (rabbit anti-T. gondii [diluted 1:3000] or vaccinated mouse [diluted 1:6000]) and secondary antibodies (anti-rabbit IgG [diluted 1:20,000] or anti-mouse IgG [diluted 1:10,000] peroxidase conjugates; Sigma) were diluted in the same blocking solution and incubated with the membranes at 37°C for 1 hr. Detection was performed by chemiluminescence (ECL Western blot detection system; Amersham Biosciences, Little Chalfont, UK) followed by exposure of the membranes to X-ray film (Hyperfilm; Amersham Biosciences).
ELISPOT and cytokine production assay
ELISPOT assays were adapted from a protocol previously described (Carvalho et al., 2001) . Nitrocellulose bottom 96-well plates (Millipore, Bedford, MA) were preincubated with an anti-IFN-␥ monoclonal antibody (clone R4-6A2; BD Biosciences Pharmingen, San Diego, CA), and blocked for 2 hr with complete DMEM. For T cell stimulation we used TLA (10 g/ml), F3 antigenic fraction (10 g/ml), SAG-derived H2-L d -binding peptides (10 M), and NIH/3T3 mouse fibroblasts (7 ϫ 10 5 cells per well) previously infected with adenoviruses encoding SAG2 (AdSAG2) or ␤-galactosidase (AdCtrl) and treated with mitomycin C (25 g/ml). Spleen cells were prepared in complete DMEM supplemented with recombinant IL-2 (100 U/ml) and added to plates at 10 6 , 3 ϫ 10 5 , or 10 4 cells per well for 20 hr of stimulation at 37°C and 5% CO 2 . A biotinylated monoclonal anti-IFN-␥ antibody (clone XMG1.2; BD Biosciences Pharmingen) was used to detect cytokine spots in combination with streptavidin-alkaline phosphatase conjugate (BD Biosciences Pharmingen). Spots were revealed with nitroblue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP) solution (Sigma). For T cell proliferation and cytokine production assays, antigens and splenocytes were prepared in the same manner as for ELISPOT assay, plated in flat-bottom 96-well cell culture plates, and incubated at 37°C and 5% CO 2 for 72 hr. IFN-␥ and IL-4 concentrations were determined in cell culture supernatants with BD OptEIA ELISA sets (BD Biosciences Pharmingen), according to the manufacturer's guide.
Immunizations and challenge
Groups of 10 BALB/c mice received two doses (10 9 PFU each) of adenovirus, 6 weeks apart, according to a protocol described by Bruna-Romero et al. (2006) . Groups of immunized mice received AdSAG1, AdSAG2, AdSAG3, or a combination of the three viruses (AdMIX). As controls, mice were immunized with a control adenovirus (AdCtrl) encoding ␤-galactosidase (AdlacZ) (Bruna-Romero et al., 1997) , or left without any immunization (NI). Serum samples were collected 11 days after each immunization, and 14 days after the last dose of adenovirus was administered mice were challenged by subcutaneous injection of 100 live tachyzoites of the RH strain diluted in PBS or by a peroral infection with 20 cysts of the P-Br strain suspended in PBS. In groups of mice infected with the RH strain, mortality was determined on a daily basis. BALB/c mice infected with P-Br were killed 45 days after challenge for microscopic determination of brain parasite burden.
Statistical analysis
All data comparisons were tested for significance by Student t test performed with InStat software (GraphPad Software, San Diego, CA), and p Ͻ 0.05 was considered significant.
RESULTS
Construction of recombinant adenoviruses
We generated three nonreplicative adenoviruses encoding the major proteins of T. gondii tachyzoite surface: SAG1 (Ad-SAG1), SAG2 (AdSAG2), and SAG3 (AdSAG3). To improve expression of SAG proteins we constructed adenoviruses with truncated versions of the corresponding coding sequences, designing primers that excluded their GPI motifs (Figs. 1A and 2A) . Although SAG1 and SAG2 were successfully expressed by this strategy (Fig. 1B and C) , the same result was not achieved with SAG3 (data not shown). Thus, we performed an additional modification on SAG3, which consisted of removal of the native signal sequence ( Fig. 2A ) and its substitution with the influenza virus hemagglutinin protein signal sequence (HASS) of the (Fig. 2B) . Fusion of HASS to the SAG3 sequence resulted in detectable expression of this protein in transfected cells (Fig. 2C) . The levels of expression of all SAG proteins were much higher when the resulting recombinant adenoviruses were used to infect HEK 293 cells (Fig. 3) . Multiple forms of recombinant SAG1, with molecular masses under 29 kDa and above 30 kDa, were detected in HEK 293 cells (Fig. 1C , lane 1 and Fig. 3, lane 2) . A similar expression pattern for this antigen was previously observed in other eukaryotic systems (Kim et al., 1994; Biemans et al., 1998) . In those studies, it was demonstrated that this pattern is related to the presence, in the SAG1 sequence, of an N-glycosylation site that, in the parasite cell, is not effectively glycosylated, but is recognized and processed in mammalian cells. This observation was confirmed after treatment of the purified protein with N-glycanase, which reduced the multiple bands corresponding to SAG1 to a single form (Kim et al., 1994; Biemans et al., 1998) .
Humoral immune responses in mice vaccinated with AdSAG1, AdSAG2, and AdSAG3
We used the recombinant adenoviruses generated to immunize female BALB/c mice. Eleven days after each vaccine dose (i.e., prime and boost), serum samples were obtained for measuring the humoral immune response. Anti-SAG antibodies were detected in animal sera by ELISA, using a tachyzoite membrane fraction enriched for GPI-anchored proteins as coating antigen (Giraldo et al., 2000) .
Immunization with AdSAG1, AdSAG2, AdSAG3, or Ad-MIX induced anti-SAG1, anti-SAG2, and anti-SAG3 IgG antibodies, as shown by the significant increase in average optical density (OD) in ELISA reactions ( (Fig. 4B) we observed a significant bias toward a Th1 response in AdSAG1-vaccinated animals (0.77 Ϯ 0.26 IgG2a ϫ 0.27 Ϯ 0.2 IgG1). This significance could not be detected for groups vaccinated with AdSAG2 (2.9 Ϯ 0.4 IgG2a ϫ 2.08 Ϯ 0.6 IgG1), AdSAG3 (0.61 Ϯ 0.11 IgG2a ϫ 0.45 Ϯ 0.1 IgG1), or AdMIX (1.46 Ϯ 0.38 IgG2a ϫ 0.92 Ϯ 0.42 IgG1). The specificity of reactions observed in ELISAs was confirmed in Western blot experiments, where sera of all vaccinated mice recognized each native SAG in total tachyzoite extracts (Fig. 4C ). Exceptions were 3 of 10 sera from the AdMIX group, which reacted with SAG2 and SAG3 but not SAG1 (data not shown).
Cellular immune responses induced by AdSAG1, AdSAG2, and AdSAG3 vaccination
Activation of T cells and production of IFN-␥ are important elements in the response to infection with T. gondii and are considered key mechanisms of protection against toxoplasmosis. We also performed experiments to assess the capacity of recombinant adenoviruses encoding SAG1, SAG2, or SAG3 to activate specific IFN-␥-producing T cells in vaccinated animals, using the ELISPOT technique.
Splenocytes from immunized BALB/c were obtained 14 days after the boost and stimulated in vitro with TLA or the membrane F3 antigenic fraction of T. gondii. These antigenic stimuli specifically induced IFN-␥ production in splenocytes isolated from AdSAG1-, AdSAG2-, and AdSAG3-immunized mice (Fig. 5) . We next attempted to define the regions in SAG1, SAG2, and SAG3 proteins that were being recognized by in vivo vaccine-induced lymphocytes. Five computer-predicted H2-L d -binding peptides (Table 1) were selected and used in the ELISPOT assays as target molecules. Two of these five peptides, SP0534/SAG1 and SP0536/SAG3, were confirmed as CD8 ϩ epitopes after inducing specific IFN-␥ secretion when presented to splenocytes from vaccinated mice ( Fig. 5A and B) . Peptide SP0535/SAG2 did not stimulate splenocytes from Ad-SAG2-vaccinated mice (Fig. 5C, left) . Nevertheless, significant and specific IFN-␥ production had been repeatedly detected when using AdSAG2-infected NIH/3T3 cells as APCs (Fig. 5C,  right) , as well as TLA or F3 as antigens for stimulation in vitro of splenocytes from AdSAG2-vaccinated mice.
To evaluate the cellular Th1/Th2 balance in response to vaccination with the recombinant adenoviruses, we measured key 
FIG. 2. Cloning of SAG3 into the adenovirus shuttle vector. (A)
The gene encoding protein SAG3 was amplified from the T. gondii genome by PCR. Primers were designed to exclude segments encoding the 5Ј signal sequence and 3Ј GPI anchoring motif, and to insert EcoRI (e) and BamHI (b) restriction sites. (B) PCR products were cloned into pcDNA3.1 in frame with a sequence encoding the influenza virus hemagglutinin signal sequence (HASS), and transferred to an adenovirus shuttle vector. (C) The final construct was transfected into HEK 293 cells to evaluate the correct expression of SAG3 (lane 1, arrow) in a Western blot assay. Lane 2, transfection control using an empty shuttle vector.
FIG. 4.
Humoral immune responses in mice vaccinated with recombinant adenoviruses. Adenoviruses expressing the tachyzoite surface antigen SAG1, SAG2, or SAG3 were used to immunize BALB/c mice. Groups of 10 animals received two doses of AdSAG1, AdSAG2, AdSAG3, or a combination of the three viruses (AdMIX). Controls included nonimmunized mice (NI) and mice that received a control adenovirus encoding an irrelevant protein (AdCtrl). The immune response was evaluated 11 days after immunization.
(A) Levels of total IgG (mean value of serum samples from 10 animals Ϯ standard deviation). (B) Levels of IgG1 and IgG2a antibody isotypes detected in sera of the same mice. Table 2 , in vitro stimulation with TLA and F3 activated strong IFN-␥ secretion by splenocytes from animals vaccinated with AdSAG1, AdSAG2, and AdSAG3. Peptides SP0534 and SP0536, which showed positive stimulation in ELISPOT, and the SAG2-derived peptide SP0535 were also tested in the cytokine assay. Again, only SAG1-and SAG3-derived peptides were able to induce IFN-␥ production at significant levels (Table 2) . When comparing IFN-␥ and IL-4 concentrations from culture supernatants, a significant difference in favor of a Th1 profile could be readily detected in splenocyte cultures from mice vaccinated with SAG-recombinant adenoviruses. Depending on the stimulus, up to a 50-fold increase in IFN-␥ over IL-4 concentration could be detected (Table 2) . These results show that vaccination with AdSAG1, AdSAG2, and AdSAG3 elicits a Th1-biased specific cellular immune response against T. gondii proteins.
Challenge with Toxoplasma gondii strains
To determine whether immune responses to SAG1, SAG2, or SAG3 induced by recombinant adenoviruses confer protection against T. gondii infection, we challenged vaccinated mice 14 days after the last dose of virus with strain P-Br (cystogenic) or RH (acute lethal infection). Challenge with P-Br strain was done by administering 20 cysts via the oral route. Forty-five days after infection, mice were killed and parasite cyst loads in the brains were counted. Vaccination with AdSAG1, AdSAG2, AdSAG3, or a combination of the three vectors (AdMIX) provided a significant decrease in brain cyst formation (Fig. 6A  and B) . In two independent experiments, the percentage reduction in cyst loads ranged between 50 and 60% for the AdSAG1 group and between 60 and 70% for the AdSAG2 group. In one experiment, AdSAG3 administration provided a 70% reduction in brain cysts, whereas vaccination with AdMIX promoted the highest level of inhibition of cyst formation, about 80%. Vaccination with the recombinant viruses, alone or in combination, did not alter the survival rate of mice challenged with the highly virulent RH strain (Fig. 6C) . 
FIG. 5.
Cellular immune responses in mice immunized with recombinant adenoviruses. Mice received two doses (10 9 PFU each) of AdSAG1 (A), AdSAG2 (B), or AdSAG3 (C) and, 14 days after immunization, the activation of specific IFN-␥-producing T cells was evaluated by ELISPOT. Total spleen cells from vaccinated and control mice were restimulated in vitro with TLA, F3 antigenic fraction, or specific class I MHC-binding peptides. Black bars, mice immunized with SAG-recombinant adenovirus; white bars, mice immunized with a control adenovirus; gray bars, nonimmunized mice.
DISCUSSION
Our interest in the use of adenoviruses as tools for the development of an anti-T. gondii vaccine arose from the fact that these vectors were demonstrated, in various disease models, such as murine malaria (Bruna-Romero et al., 2001) , hepatitis C (Bruna-Romero et al., 1997) , and AIDS in monkeys (Shiver et al., 2002) , to be extremely efficient inducers of antigen-specific CD4 ϩ T and CD8 ϩ T cells, which are essential for control of T. gondii infection.
To construct recombinant adenoviruses, SAG genes were altered with the purpose of improving protein expression. Thus, we amplified and cloned each SAG gene without the 3Ј-end GPI anchoring motifs. Previous works from our research group, carried out with Plasmodium yoelii circumsporozoite protein (CS), showed that this modification improves the expression this protozoan surface protein in mammalian cells and, therefore, enhances the immune response obtained after adenovirus vaccination (Bruna-Romero et al., 2004) . For SAG3 one additional alteration was performed in order to allow expression in mammalian cells, and this was substitution of the native N-terminal signal sequence of the protein for the influenza virus hemagglutinin signal sequence (HASS) (Hüssy et al., 1996) . Those modifications were based on the assumption that mammalian cellular receptors involved in transport of recently expressed proteins to the endoplasmic reticulum, and the proteins responsible for posttranslational modifications, are not adapted to recognition of protozoan signal sequences or GPI motifs, and that this failure could impair final expression of the protein. As result of this genetic manipulation, all three recombinant adenoviruses were able to induce expression of high levels of single proteins that were readily recognized by sera of animals infected with T. gondii.
Analysis of the humoral immune responses of mice vaccinated with AdSAG1, AdSAG2, AdSAG3, or a combination of these three viruses showed that the recombinant adenoviruses were efficient in inducing production of IgG antibodies against these parasite surface proteins, which were detected by ELISA and Western blot in all vaccinated animals. This result shows that infection, genetic transfer, and expression of proteins in vivo with recombinant adenoviruses is a reliable and reproductive system, as seen in in vitro assays. When comparing the three recombinant viruses, AdSAG2 was the most efficient in eliciting antigen-specific antibodies. There was, at least in animals vaccinated with AdSAG1, a bias to express higher levels of IgG2a relative to IgG1 levels, indicative of activation of a Th1 response by helper T cells, which is important for protection against the development of the disease. This was further confirmed when cytokines were measured in supernatants of lymphocyte cultures.
Some studies have generated indirect evidences that IgG antibodies are important for protection against T. gondii infection. It was observed that B cell-deficient mice are highly susceptible to brain inflammatory pathology in chronic infections with the parasite, despite presenting similar levels of serum and tissue proinflammatory cytokines, such as IFN-␥. Adoptive transfer of polyclonal anti-T. gondii IgG antibodies to these mice prevented both pathology and mortality (Kang et al., 2000) . Also, vaccination of B cell-deficient mice with attenuated ts-4 tachyzoites did not induce protection against mortality after challenge with a virulent strain of T. gondii, as observed in control animals. This failure to immunize mice lacking B cells was not associated with deficient T cell function or IFN-␥ production, and its effects could be partially reverted (survival time lengthened) by administration of anti-T. gondii immune sera (Sayles et al., 2000) . Protection mediated by IgG antibodies was associated with neutralization of free parasites, observed in in vitro experiments (Sayles et al., 2000) . A number of studies have indicated that SAG1 and SAG3 are involved in host cell attachment/invasion by tachyzoites (Grimwood and Smith, 1992; Mineo et al., 1993; Mineo and Kasper, 1994; Dzierszinski et al., 2000; Robinson et al., 2004) . Although neutralization of parasites by antibodies was not tested in our experiments, we speculate that production of blocking anti-SAG1/3 IgG antibodies could be one of the mechanisms contributing to control of the dissemination of parasites in vaccinated animals. We further explored the cellular immune responses in adenovirus-vaccinated mice by detecting activated T cells by ELISPOT assay or by detecting cytokines in supernatants of cultured splenocytes. AdSAG1-, AdSAG2-, and AdSAG3-vaccinated mice showed specific activation of T cells, as determined by the secretion of IFN-␥ by spleen cells stimulated by SAG antigens present in total tachyzoite lysate antigen or in extracts of membrane-purified proteins of T. gondii. In mice vaccinated with AdSAG1 and AdSAG3, part of the IFN-␥ production could be attributed to two specific regions, mapped in SAG1 and SAG3 sequences, that represented CD8 ϩ T cell epitopes. These are encouraging results, because many studies (Suzuki and Remington, 1988; Brown and McLeod, 1990; Khan et al., 1999) have emphasized the importance of the CD8 ϩ lymphocyte subset for controlling T. gondii infection. On the other hand, the helper CD4 ϩ T subgroup appears to cooperate in the control of chronic infection by means of IFN-␥ production, and by priming of redundant CD8 ϩ T cells (Gazzinelli et al., 1991 (Gazzinelli et al., , 1992 . The IFN-␥ specific against SAG2 could not be mapped to any region in this protein. However, because this immune response was detected with AdSAG2-infected NIH/3T3 fibroblasts, bearing only MHC-I molecules on their surface, it is feasible to believe that specific CD8 ϩ T cells for this proteins must be induced. In those assays, to differentiate the spots corresponding to T cells specific for SAG2 from those related to cells specific for viral epitopes, we tested the spleen cells of vaccinated mice against AdlacZ-infected APCs. In addition, to minimize the reaction to viral antigens, we opted to test splenocytes collected after just one dose of recombinant adenovirus. A significant number of SAG2-responding CD8 ϩ T cells was detected in AdSAG2-immunized mice (Fig. 5C, right) . This difference in results is not surprising if we consider that infected cells present a variety of SAG2 epitopes that stimulate different CD8 ϩ clones and generate a much broader response than that evaluated with SP0535/SAG2 peptide. Therefore, an adequate evaluation of the CD8 ϩ response employing H2- binding peptides demands the determination of new SAG2 epitopes. When comparing IFN-␥ and IL-4 production by spleen cells of vaccinated mice, the development of a Th1-biased immune response could be clearly detected in animals that received the recombinant adenoviruses. Such direct activation of Th1 responses was not seen in other models of vaccination that involved the use of tachyzoite extracts (Yap et al., 1998) , SAG1 and SAG2 purified from tachyzoite membrane (Bonenfant et al., 2001) , or recombinant SAG1 and SAG2 proteins (Bulow and Boothroyd, 1991; Letscher-Bru et al., 1998; Haumont et al., 2000; Mishima et al., 2001) . In those models, the production of IFN-␥ and IgG2a was dependent on coadministration of an adjuvant, such as recombinant IL-12 or heat-labile enterotoxins. A natural Th1 deviation, similar to that occurring in adenovirus-vaccinated animals, was observed in vaccination with plasmid DNA encoding SAG1 (Nielsen et al., 1999; Couper et al., 2003; Mohamed et al., 2003) . This characteristic is associated with immunomodulatory properties of CpG motifs present in bacterial plasmids used in vaccination (Mohamed et al., 2003) . It is possible that similar mechanisms of immunomodulation could be activated by adenoviral proteins, such as the hexon, penton, or fiber (Molinier-Frenkel et al., 2002 .
Vaccination of mice with AdSAG1, AdSAG2, AdSAG3, or a mixture of the three reduced brain cyst load after challenge with the P-Br strain. The percentage reduction was comparable between the various adenovirus-vaccinated groups, and slightly higher in the AdMIX group. This result is consistent with previous observations in different vaccination models, which showed that SAG1, SAG2, and SAG3 antigens, alone or in combination, confer partial protection against cystogenic strains of T. gondii. In one study, Letscher-Bru et al. (1998) obtained 40% reduction in brain cysts after immunization of CBA/J mice with recombinant SAG1 plus IL-12, whereas in a experiment by Mishima et al. (2001) , recombinant SAG2 and a recombinant protein mix that included SAG1, SAG2, and SAG3, both with Freund's complete adjuvant, completely inhibited brain cyst formation after infection of vaccinated BALB/c mice with the Beverley strain. DNA vaccination with the SAG1 gene reduced brain cyst formation in BALB/c mice challenged with Fukaya (Saito et al., 2001; Mohamed et al., 2003) and Beverley strains (Couper et al., 2003) and protected C57BL/6 mice from infection with the ME49 strain (Angus et al., 2000) , but in none of those cases was complete elimination of cysts observed. However, it is not possible to compare results obtained with the adenoviruses with other vaccines in terms of efficacy, because of differences in virulence between the T. gondii strains used for challenges, the variety of mouse strains used, and the route of administration and dose of parasites given to animals.
On the other hand, vaccination with recombinant adenoviruses did not protect mice against acute infection with the RH strain, which indicates that the response did not develop as fast and as intensely as necessary to control tachyzoite replication. In actuality, there are only a few reports of recombinant vaccines capable of controlling infection with the RH strain. In studies by Angus et al. (2000) , Chen et al. (2002) , Roque-Reséndiz et al. (2004) , and Fachado et al. (2003) , using recombinant or viral vaccines, the immunity induced was capable of delaying the death of vaccinated mice by only a few days. The most successful model was that developed by Nielsen et al. (1999) , who reported up to 80% complete protection of BALB/c mice after vaccination with a plasmid encoding SAG1.
Complete, long-lasting protection against RH lethality, with no signs of acute disease or establishment of chronic cysts in various strains of mice, was observed only after administration of live tachyzoites of the attenuated ts-4 strain (Gazzinelli et al., 1991) . The variety of antigens that are presented to the host immune system could account for the more effective results obtained with live attenuated strains in comparison with recombinant adenovirus vaccines. It is possible that activation of responses against the RH strain-and improvement of partial protection obtained against the cystogenic strains-could be achieved with a combination of antigens that would simultaneously target attachment/invasion and metabolic proteins of the parasite. In the case of cystogenic strains, it is still necessary to consider the association of antigens expressed in the various developmental stages of T. gondii.
In summary, this work shows for the first time the use of recombinant adenoviruses as vectors for immunization with tachyzoite surface antigens. This system was shown to be extremely efficient in inducing the expression of parasite antigens in host cells and in eliciting humoral and cellular immune responses that led to a high degree of protection of animals challenged with the P-Br strain of T. gondii.
